Financings/Collaborations In Brief: Microcide/J&J
Executive Summary
Microcide/J&J: Sign research and licensing agreement to develop antibiotics for Gram-positive resistant infections. Under the agreement announced Oct. 25, Mountain View, Calif.-based Microcide receives an initial $3 mil. licensing fee and $5 mil. equity investment, along with research funding, milestone payments and royalties on worldwide sales. The collaboration is set for three years, with an option to extend the agreement for an additional year...